MedWatch

Bavarian Nordic releases more specific guidance - downgrades expectations

Although Covid-19 has not disrupted sales of Bavarian Nordic's ebola vaccine, its hands are still tied in other business areas, leading the firm to downgrade its financial guidance.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Bavarian Nordic's potential Covid-19 vaccine has been hogging the spotlight over the past few months, but the company has also been working on its other business areas - where Covid-19 is more of a hindrance than a help.

This has led Bavarian Nordic to release more specific financial guidance at the lower end of its original expectations.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Sanofi reduces US insulin prices for the uninsured

While bills to introduce a price cap on insulin are being discussed in the US Senate, Sanofi has beaten them to the punch and reduced the price of insulin products for US diabetes patients without insurance.

Further reading

Related articles

Latest news

See all jobs